IL-2 + G-CSF mobilization was safe, may lead to a more immunologically functional graft without impairing hematologic recovery. Limitations of this combined approach to SC mobilization include a decrease in the number of CD34+ cells mobilized with the combined cytokines and the short duration of the increased number of anti-tumor effector cells after transplant. This evidence concerns the gene CSF3 and neoplasm.